| Heart disease and stroke statistics—2012 update: a report from the American Heart Association Writing Group Members, VL Roger, AS Go, DM Lloyd-Jones, EJ Benjamin, ... Circulation 125 (1), e2-e220, 2012 | 31246* | 2012 |
| Dapagliflozin in patients with chronic kidney disease HJL Heerspink, BV Stefánsson, R Correa-Rotter, GM Chertow, T Greene, ... New England Journal of Medicine 383 (15), 1436-1446, 2020 | 3509 | 2020 |
| Efficacy and safety of benazepril for advanced chronic renal insufficiency FF Hou, X Zhang, GH Zhang, D Xie, PY Chen, WR Zhang, JP Jiang, ... New England Journal of Medicine 354 (2), 131-140, 2006 | 882 | 2006 |
| Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial Y Huo, J Li, X Qin, Y Huang, X Wang, RF Gottesman, G Tang, B Wang, ... Jama 313 (13), 1325-1335, 2015 | 783 | 2015 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 492 | 2019 |
| Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China X Xu, J Sun, S Nie, H Li, Y Kong, M Liang, J Hou, X Huang, D Li, T Ma, ... Nature medicine 26 (8), 1193-1195, 2020 | 481 | 2020 |
| Long-term exposure to air pollution and increased risk of membranous nephropathy in China X Xu, G Wang, N Chen, T Lu, S Nie, G Xu, P Zhang, Y Luo, Y Wang, ... Journal of the American Society of Nephrology 27 (12), 3739-3746, 2016 | 440 | 2016 |
| miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes X Zhong, ACK Chung, HY Chen, Y Dong, XM Meng, R Li, W Yang, ... Diabetologia 56, 663-674, 2013 | 401 | 2013 |
| Environmental pollution and kidney diseases X Xu, S Nie, H Ding, FF Hou Nature Reviews Nephrology 14 (5), 313-324, 2018 | 355 | 2018 |
| Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the … DC Wheeler, BV Stefánsson, N Jongs, GM Chertow, T Greene, FF Hou, ... The lancet Diabetes & endocrinology 9 (1), 22-31, 2021 | 342 | 2021 |
| Epidemiology and clinical correlates of AKI in Chinese hospitalized adults X Xu, S Nie, Z Liu, C Chen, G Xu, Y Zha, J Qian, B Liu, S Han, A Xu, X Xu, ... Clinical Journal of the American Society of Nephrology 10 (9), 1510-1518, 2015 | 330 | 2015 |
| Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency FF Hou, D Xie, X Zhang, PY Chen, WR Zhang, M Liang, ZJ Guo, JP Jiang Journal of the American Society of Nephrology 18 (6), 1889-1898, 2007 | 328 | 2007 |
| Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials HJL Heerspink, T Greene, H Tighiouart, RT Gansevoort, J Coresh, ... The lancet Diabetes & endocrinology 7 (2), 128-139, 2019 | 272 | 2019 |
| Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis S Hao, W He, Y Li, H Ding, Y Hou, J Nie, FF Hou, M Kahn, Y Liu Journal of the American Society of Nephrology 22 (9), 1642-1653, 2011 | 268 | 2011 |
| Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation SX Liu, FF Hou, ZJ Guo, R Nagai, WR Zhang, ZQ Liu, ZM Zhou, M Zhou, ... Arteriosclerosis, Thrombosis, and Vascular Biology 26 (5), 1156-1162, 2006 | 264 | 2006 |
| Advanced Oxidation Protein Products Activate Vascular Endothelial Cells via a RAGE-Mediated Signaling Pathway ZJ Guo, HX Niu, FF Hou, L Zhang, N Fu, R Nagai, X Lu, BH Chen, ... Antioxidants & Redox Signaling 10 (10), 1699-1712, 2008 | 262 | 2008 |
| Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies J Coresh, HJL Heerspink, Y Sang, K Matsushita, J Arnlov, BC Astor, ... The lancet Diabetes & endocrinology 7 (2), 115-127, 2019 | 258 | 2019 |
| Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease AK Cheung, TI Chang, WC Cushman, SL Furth, FF Hou, JH Ix, GA Knoll, ... Kidney international 99 (3), 559-569, 2021 | 239 | 2021 |
| Alteration of the gut microbiota in Chinese population with chronic kidney disease S Jiang, S Xie, D Lv, P Wang, H He, T Zhang, Y Zhou, Q Lin, H Zhou, ... Scientific reports 7 (1), 2870, 2017 | 231 | 2017 |
| Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial HJL Heerspink, BV Stefansson, GM Chertow, R Correa-Rotter, T Greene, ... Nephrology Dialysis Transplantation 35 (2), 274-282, 2020 | 225 | 2020 |
